Alan Kimura, MD
Retina Specialist · Denver, CONPI 1851343214
Payments from drug & device makers
What this record shows
This record is dominated by other: $340,087 of the $545,822 with a category attached, or 62.3%. US Retina LLC accounts for 84.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $360,434 and has fallen 97.7% since, to $8,140 in 2025. Among retina specialist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $2950.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$460K
- Johnson & Johnson$56K
- Spark Therapeutics, Inc.$22K
- Biogen$4K
- AbbVie$976
- Genentech USA, Inc.$829
- plus $3K from 17 others
What the payments were for
- Consulting fees$51,4709%
- Speaking & faculty fees$20,0424%
- Grants$830%
- Travel & lodging$8,8082%
- Food & beverage$4,7011%
- Education$7500%
- Gifts$190%
- Entertainment$1070%
- Ownership interest$119,75422%
- Other$340,08762%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 9 | $459,844 |
| Johnson & Johnson | 42 | $55,625 |
| Spark Therapeutics, Inc. | 16 | $21,824 |
| Biogen | 15 | $4,128 |
| AbbVie(2 entities) | 9 | $976 |
| Genentech USA, Inc. | 19 | $829 |
| Regeneron Healthcare Solutions, Inc. | 23 | $549 |
| Genentech, Inc. | 6 | $520 |
| Coherus Oncology, Inc. | 6 | $231 |
| Novartis | 12 | $203 |
| Janssen Global Services, LLC | 2 | $165 |
| Apellis Pharmaceuticals, Inc. | 3 | $165 |
| Eyepoint US, Inc. | 3 | $149 |
| Notal Vision, Inc. | 2 | $112 |
| Optos, Inc. | 2 | $107 |
| Bausch & Lomb Americas Inc. | 4 | $87 |
| Alimera Sciences, Inc. | 4 | $82 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Astellas Pharma US Inc | 3 | $71 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Alcon | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Topcon Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$545,822 in reported general payments places this provider in the 95th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dorzolamide Hcl | 22 | $519 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Denver
- Brian JoondephDenver$92K
- Nancy ChristmasDenver$12K
- Jesse SmithDenver$7K
- Miriah TeeterDenver$3K
- Diana ReevesDenver$3K
- Mariana HarasawaDenver$332
- Murtaza AdamParker$548K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.